HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Medical System (867.HK) - The Concerns Are On "PLENITY"

Chongqing Zhifei Biological Products (300122.CH) - Could Zhifei Support Its Valuation?

Chongqing Zhifei Biological Products- Promising Future After Successful Renewal of Contract with MSD

Industry Report - Insights on China Vaccine Industry

Beijing Wantai Biological (603392.CH) - After A 3839% Rally, Let's Look at Some Concerns

Gravity Works As WeWork Doesn't; Now Plan B

Bifurcated Chinese Express Market Developing

Equity Bottom-Up

<p>Recently, <a href="https://www.smartkarma.com/entities/cansino-biologics-inc" target="_blank" data-smartkarma-citation="entities:27739:1" rel="noopener">CanSino Biologics Inc (6185 HK)</a> released the performance announcement in 2020. CanSino is expected to achieve the revenue in 2020 of RMB24.89 million, up 990.06% YoY. The Company's net loss attributed to shareholders could reach RMB407 million, up 159.63% YoY. Net loss after deducting non-recurring gains and losses is expected to reach RMB522 million, up 199.09% YoY. Meanwhile, CanSino had filed an application with the NMPA for conditional marketing authorization of the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (“Ad5-nCoV”, trade name: Convidecia™) and NMPA had accepted the application. On the other hand, according to the listing rules of the SSE STAR Market, CanSino needs to become profitable or successfully commercialize its products by at least 2024, or it will trigger delisting conditions. So, will the COVID-19 vaccine be CanSino's turning point?</p>

Recently, CanSino Biologics Inc (6185 HK) released the performance announcement in 2020. CanSino is expected to achieve the revenue in 2020 of RMB24.89 million, up 990.06% YoY. The Company's net loss attributed to shareholders could reach RMB407 million, up 159.63% YoY. Net loss after deducting non-recurring gains and losses is expected to reach RMB522 million, up 199.09% YoY. Meanwhile, CanSino had filed an application with the NMPA for conditional marketing authorization of the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (“Ad5-nCoV”, trade name: Convidecia™) and NMPA had accepted the application. On the other hand, according to the listing rules of the SSE STAR Market, CanSino needs to become profitable or successfully commercialize its products by at least 2024, or it will trigger delisting conditions. So, will the COVID-19 vaccine be CanSino's turning point?